These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 18225458)

  • 1. Testosterone depot injection in male hypogonadism: a critical appraisal.
    Yassin AA; Haffejee M
    Clin Interv Aging; 2007; 2(4):577-90. PubMed ID: 18225458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.
    Saad F; Kamischke A; Yassin A; Zitzmann M; Schubert M; Jockenhel F; Behre HM; Gooren L; Nieschlag E
    Asian J Androl; 2007 May; 9(3):291-7. PubMed ID: 17486268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
    J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone undecanoate in the treatment of male hypogonadism.
    Edelstein D; Basaria S
    Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
    Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
    J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations.
    Giagulli VA; Triggiani V; Corona G; Carbone D; Licchelli B; Tafaro E; Resta F; Sabbà C; Maggi M; Guastamacchia E
    Curr Pharm Des; 2011; 17(15):1500-11. PubMed ID: 21521164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging medication for the treatment of male hypogonadism.
    Aydogdu A; Swerdloff RS
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):255-66. PubMed ID: 27552127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new testosterone gel (fortesta) for hypogonadism.
    Med Lett Drugs Ther; 2011 Apr; 53(1362):29-30. PubMed ID: 21502933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study.
    Wolf J; Keipert D; Motazedi H; Ernst M; Nettleship J; Gooren L
    Aging Male; 2017 Dec; 20(4):225-234. PubMed ID: 28812471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone therapy--what, when and to whom?
    Jockenhövel F
    Aging Male; 2004 Dec; 7(4):319-24. PubMed ID: 15799128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A long-acting depot formulation of testosterone (Aveed).
    Med Lett Drugs Ther; 2014 Mar; 56(1439):26-8. PubMed ID: 24691149
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of testosterone gel in the treatment of male hypogonadism.
    Lakshman KM; Basaria S
    Clin Interv Aging; 2009; 4():397-412. PubMed ID: 19966909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
    Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
    J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
    von Eckardstein S; Nieschlag E
    J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism.
    Kaminetsky JC; Moclair B; Hemani M; Sand M
    J Sex Med; 2011 Apr; 8(4):1186-96. PubMed ID: 21269402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men.
    Dinsmore WW; Wyllie MG
    BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with the new long-acting injectable testosterone undecanoate. Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male, 9-12 February 2006, Salzburg, Austria.
    Morales A; Nieschlag E; Schubert M; Yassin AA; Zitzmann M; Oettel M
    Aging Male; 2006 Dec; 9(4):221-7. PubMed ID: 17178558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.